United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Report 2017

December 2017 | 105 pages | ID: U9691C34736EN
QYResearch

Abstracts

In this report, the United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in these regions, from 2012 to 2022 (forecast).

United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications market competition by top manufacturers/players, with Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Roche
• Dako (Agilent Technologies)
• Merck
• BD
• Abbott
• Genesys Biolabs(20/20GeneSystems)
• Affymetrix
• Agendia
• ALMAC
• Arrayit
• Biocartic
• BG Medicine
• Thermo Fisher
• BGI

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Consumables
• Services
• Software

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Oncology
• Cardiology
• Neurology
• Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Report 2017

1 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS OVERVIEW

1.1 Product Overview and Scope of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
1.2 Classification of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product Category
  1.2.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Consumables
  1.2.4 Services
  1.2.5 Software
1.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market by Application/End Users
  1.3.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Oncology
  1.3.3 Cardiology
  1.3.4 Neurology
  1.3.5 Other
1.4 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market by Region
  1.4.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Commercializing Biomarkers in Therapeutic and Diagnostic Applications Status and Prospect (2012-2022)
  1.4.3 Southwest Commercializing Biomarkers in Therapeutic and Diagnostic Applications Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Status and Prospect (2012-2022)
  1.4.5 New England Commercializing Biomarkers in Therapeutic and Diagnostic Applications Status and Prospect (2012-2022)
  1.4.6 The South Commercializing Biomarkers in Therapeutic and Diagnostic Applications Status and Prospect (2012-2022)
  1.4.7 The Midwest Commercializing Biomarkers in Therapeutic and Diagnostic Applications Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Commercializing Biomarkers in Therapeutic and Diagnostic Applications (2012-2022)
  1.5.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2022)
  1.5.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2022)

2 UNITED STATES COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Average Price by Players/Suppliers (2012-2017)
2.4 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Competitive Situation and Trends
  2.4.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Rate
  2.4.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Region (2012-2017)
3.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Region (2012-2017)
3.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Price by Region (2012-2017)

4 UNITED STATES COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Type (2012-2017)
4.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Price by Type (2012-2017)
4.4 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate by Type (2012-2017)

5 UNITED STATES COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Application (2012-2017)
5.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Dako (Agilent Technologies)
  6.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Merck
  6.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 BD
  6.4.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Abbott
  6.5.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Genesys Biolabs(20/20GeneSystems)
  6.6.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Affymetrix
  6.7.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Agendia
  6.8.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 ALMAC
  6.9.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Arrayit
  6.10.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Biocartic
6.12 BG Medicine
6.13 Thermo Fisher
6.14 BGI

7 COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MANUFACTURING COST ANALYSIS

7.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Forecast by Type (2017-2022)
11.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Forecast by Application (2017-2022)
11.4 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (K Units) by Type (2012-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Market Share by Type (Product Category) in 2016
Figure Consumables Product Picture
Figure Services Product Picture
Figure Software Product Picture
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2016
Figure Oncology Examples
Table Key Downstream Customer in Oncology
Figure Cardiology Examples
Table Key Downstream Customer in Cardiology
Figure Neurology Examples
Table Key Downstream Customer in Neurology
Figure Other Examples
Table Key Downstream Customer in Other
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Million USD) by Region (2012-2022)
Figure The West Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) and Growth Rate (2012-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Players/Suppliers
Figure 2017 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Players/Suppliers
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Players/Suppliers
Figure 2017 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Players/Suppliers
Table United States Market Commercializing Biomarkers in Therapeutic and Diagnostic Applications Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Commercializing Biomarkers in Therapeutic and Diagnostic Applications Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share of Top 3 Players/Suppliers
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Category
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Region (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Region (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Region (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Region in 2016
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Region (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Region (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Region in 2016
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Price (USD/Unit) by Region (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Type (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Type (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Share by Type (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Type in 2016
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Type (2012-2017)
Figure Revenue Market Share of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Type in 2016
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Price (USD/Unit) by Types (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate by Type (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units) by Application (2012-2017)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share by Application in 2016
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate by Application (2012-2017)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate by Application (2012-2017)
Table Roche Basic Information List
Table Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Dako (Agilent Technologies) Basic Information List
Table Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table BD Basic Information List
Table BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Abbott Basic Information List
Table Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Genesys Biolabs(20/20GeneSystems) Basic Information List
Table Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Affymetrix Basic Information List
Table Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Agendia Basic Information List
Table Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table ALMAC Basic Information List
Table ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Arrayit Basic Information List
Table Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Growth Rate (2012-2017)
Figure Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in United States (2012-2017)
Figure Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share in United States (2012-2017)
Table Biocartic Basic Information List
Table BG Medicine Basic Information List
Table Thermo Fisher Basic Information List
Table BGI Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Figure Manufacturing Process Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Figure Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain Analysis
Table Raw Materials Sources of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Players/Suppliers in 2016
Table Major Buyers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Table Distributors/Traders List
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) Forecast by Type in 2022
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) Forecast by Application in 2022
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Share Forecast by Region (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Share Forecast by Region (2017-2022)
Figure United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources